Flupyradifurone. HPLC Method

Similar documents
ASSAY AND IMPURITY METHOD FOR DURACOR TABLETS BY HPLC

Title Revision n date

RITONAVIRI COMPRESSI RITONAVIR TABLETS. Final text for addition to The International Pharmacopoeia (July 2012)

TENOFOVIR TABLETS: Final text for addition to The International Pharmacopoeia (June 2010)

INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LAMIVUDINE TABLETS

Relative Measurement of Zeaxanthin Stereoisomers by Chiral HPLC

ARTESUNATE TABLETS: Final text for revision of The International Pharmacopoeia (December 2009) ARTESUNATI COMPRESSI ARTESUNATE TABLETS

ARTENIMOLUM ARTENIMOL. Adopted revised text for addition to The International Pharmacopoeia

Rebaudioside a From Multiple Gene Donors Expressed in Yarrowia Lipolytica

PROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN The International Pharmacopoeia: REVISION OF ph test ABACAVIR ORAL SOLUTION (JULY 2012)

DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS

The Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph.

STANDARD OPERATING PROTOCOL (SOP)

Determination of 6-Chloropicolinic Acid (6-CPA) in Crops by Liquid Chromatography with Tandem Mass Spectrometry Detection. EPL-BAS Method No.

PAPRIKA EXTRACT SYNONYMS DEFINITION DESCRIPTION FUNCTIONAL USES CHARACTERISTICS

IJPAR Vol.3 Issue 4 Oct-Dec-2014 Journal Home page:

CYCLOSERINI CAPSULAE - CYCLOSERINE CAPSULES (AUGUST 2015)

LEVONORGESTREL AND ETHINYLESTRADIOL TABLETS. (January 2012) DRAFT FOR COMMENT

This revision also necessitates a change in the table numbering in the test for Organic Impurities.

CORESTA Recommended Method No. 78

10 Sulfaquinoxaline H N O S O. 4-amino-N-quinoxalin-2-ylbenzenesulfonamide C 14 H 12 N 4 O 2 S MW: CAS No.:

ZIDOVUDINE, LAMIVUDINE AND ABACAVIR TABLETS Draft proposal for The International Pharmacopoeia (September 2006)

CORESTA RECOMMENDED METHOD NÄ 9

Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry Journal home page:

Analytical Method for 2, 4, 5-T (Targeted to Agricultural, Animal and Fishery Products)

Development and validation of stability indicating RP-LC method for estimation of calcium dobesilate in pharmaceutical formulations

METHOD 8316 ACRYLAMIDE, ACRYLONITRILE AND ACROLEIN BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

Ergovaline. [Methods listed in the Feed Analysis Standards] 1 Liquid chromatography Note 1, 2 [Feed Analysis Standards, Chapter 5, Section 2

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD ESTIMATION OF TOLVAPTAN IN BULK PHARMACEUTICAL FORMULATION

A HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ASSAY FOR LERCANIDIPINE HYDROCHLORIDE

Fig.1. Denatonium benzoate (DB) chemical structure

Validation of Changes to the USP Assay Method for Ibuprofen Tablets

Draft monograph for inclusion in. The International Pharmacopoeia. Dextromethorphani solutionum peroralum - Dextromethorphan oral solution

SIMULTANEOUS ESTIMATION OF VALSARTAN AND HYDROCHLOROTHIAZIDE IN TABLETS BY RP-HPLC METHOD

Quetiapine Tablets. Expert Committee Monographs Chemical Medicines 4 Reason for Revision Compliance

Antioxidant. [Summary of antioxidant]

SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS Draft proposal for The International Pharmacopoeia (September 2010)

EASI-EXTRACT BIOTIN Product Code: P82 / P82B

Development and Validation for Simultaneous Estimation of Sitagliptin and Metformin in Pharmaceutical Dosage Form using RP-HPLC Method

RP-HPLC Method Development and Validation of Abacavir Sulphate in Bulk and Tablet Dosage Form

RP- HPLC and Visible Spectrophotometric methods for the Estimation of Meropenem in Pure and Pharmaceutical Formulations

METHOD DEVELOPMENT AND VALIDATION BY RP-HPLC FOR ESTIMATION OF ZOLPIDEM TARTARATE

SIMULTANEOUS DETERMINATION OF ATORVASTATIN AND EZETIMIBE BY RP-HPLC IN PURE AND PHARMACEUTICAL DOSAGE FORM

Lutein Esters from Tagetes Erecta

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ESTIMATION OF LACOSAMIDE IN BULK AND ITS PHARMACEUTICAL FORMULATION

Journal of Chemical and Pharmaceutical Research, 2013, 5(1): Research Article

Analysis of Amino Acids Derived Online Using an Agilent AdvanceBio AAA Column

REVERSE PHASE HPLC METHOD FOR THE ANALYSIS OF ALFUZOSIN HYDROCHLORIDE IN PHARMACEUTICAL DOSAGE FORMS

Pelagia Research Library

REVISED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA RETINOL CONCENTRATE, OILY FORM. (August 2010)

Available online at Scholars Research Library

Official Journal of the European Union. (Non-legislative acts) REGULATIONS

CLINDAMYCIN PALMITATE

Analysis of Isoflavones with the PerkinElmer Flexar FX-15 UHPLC System Equipped with a PDA Detector

International Journal of Medicine and Pharmaceutical Research. International Journal of Medicine and Pharmaceutical Research

STANDARD OPERATING PROTOCOL (SOP)

CORESTA RECOMMENDED METHOD N 8

RP-HPLC Analysis of Temozolomide in Pharmaceutical Dosage Forms

Determination of Water- and Fat-Soluble Vitamins in Nutritional Supplements by HPLC with UV Detection

EMTRICITABINE AND TENOFOVIR TABLETS

Neosolaniol. [Methods listed in the Feed Analysis Standards]

Simultaneous estimation of Metformin HCl and Sitagliptin in drug substance and drug products by RP-HPLC method

CHAPTER 8 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) ANALYSIS OF PHYTOCHEMICAL CONSTITUENTS OF M. ROXBURGHIANUS AND P. FRATERNUS PLANT EXTRACTS

Tenofovir disoproxil fumarate (Tenofoviri disoproxili fumaras)

Heparin Sodium ヘパリンナトリウム

contents of the monograph in effect today. Please refer to the current edition of the USP NF for official text.

Development, Estimation and Validation of Lisinopril in Bulk and its Pharmaceutical Formulation by HPLC Method

Pelagia Research Library

Rapid and sensitive UHPLC screening for water soluble vitamins in sports beverages

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PAEDIATRIC RETINOL ORAL SOLUTION (August 2010)

Tramadol Hydrochloride Extended-Release Tablets. Expert Committee Chemical Medicines Monographs 2 Reason for Revision Compliance

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA EFAVIRENZ, EMTRICITABINE AND TENOFOVIR TABLETS

ABACAVIR SULFATE Proposal for revision of The International Pharmacopoeia (August 2012)

1 out of 8. Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 86th Meeting 2018 ERYTHROSINE

Available online Research Article

Determination of Bisphenol A in Milk Powder using a Chromolith HighResolution RP-18 endcapped column

Jagua (Genipin-Glycine) Blue (Tentative)

3-Acetyldeoxynivalenol. 15-Acetyldeoxynivalenol

Scholars Research Library. Der Pharmacia Lettre, 2015, 7 (5):44-49 (

Revision Bulletin 28 Jul Aug 2017 Chemical Medicines Monographs 3

Estimation of Zanamivir Drug present in Tablets using RP-HPLC Method

Research Article DEVOLOPMENT OF RP-HPLC METHOD AND IT S VALIDATION FOR SIMULTANEOUS ESTIMATION OF SITAGLIPTIN AND METFORMIN

ISSN: ; CODEN ECJHAO E-Journal of Chemistry 2011, 8(3),

World Journal of Pharmaceutical Research

Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016.

E17 ETHYLCELLULOSE. Revision 3 Stage 4

FORMULATION CHOICE. How and why they are chosen. Dr Andy Fowles On behalf of ECPA Specification Expert Group

DEVELOPMENT AND VALIDATION OF NEW HPLC METHOD FOR THE ESTIMATION OF PALIPERIDONE IN PHARMACEUTICAL DOSAGE FORMS

EASI-EXTRACT FOLIC ACID Product Code: P81 / P81B

International Journal of Pharma and Bio Sciences DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF STRONTIUM RANELATE IN SACHET

A high-performance liquid chromatography (HPLC) method for determination of chlorogenic acid and emodin in Yinhuang Jiangzhi Tea

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR QUANTITATIVE ANALYSIS OF TRAMADOL IN PURE AND PHARMACEUTICAL FORMULATIONS

Tentu Nageswara Rao et al. / Int. Res J Pharm. App Sci., 2012; 2(4): 35-40

ISSN (Print)

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR QUANTITATIVE ANALYSIS TOLBUTAMIDE IN PURE AND PHARMACEUTICAL FORMULATIONS

SUCROSE OLIGOESTERS TYPE I

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

ANALYTICAL TECHNIQUES FOR THE QUALITY OF ANTI- AIDS DRUGS

Transcription:

HPLC Method CIPAC Collaboration Trial according to CIPAC Information Sheet No 308 by Alexandra Michel Crop Science Division Bayer Aktiengesellschaft Alfred-Nobel-Str. 50, Building 6820 40789 Monheim am Rhein Germany May 2017

FLUPYRADIFURONE 987 Chemical name: 4-[[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)ao]furan- 2(5H)-on ISO common name: CAS-No.: 951659-40-8 Structure: Cl F N N F O O Molecular mass: 288.7 Empirical formula: C 12 H 11 Cl F 2 N 2 O 2 m.p.: 69 C b.p.: Decomposition occurs at about 270 C before boiling point is reached Solubility: 1,2-dichloromethane, ethylacetate, methanol > 250 g/l; toluene 3.7 g/l (all at 20 C) Description: The technical product is a white to beige powder. FLUPYRADIFURONE TECHNICAL 987/TC/M/- 1 Sampling. Take at least 100 g*. Grind the sample thoroughly in a mortar. *(for this trial less amount is provided; please grind the entire sample) 2 Identity tests 2.1 HPLC. Use the HPLC method described below. The relative retention time of in the sample solution should not deviate by more than 2% from that of the calibration solution. 2.2 UV spectrometry. Record the UV spectrum during the HPLC deteration. The UV spectrum obtained from the sample should not differ significantly from that of the standard. (Fig. 1) 2.3 Infrared. Prepare by direct application pure flupyradifurone and the sample on an ATR unit. Scan from 4000 to 550 cm-1. The spectrum produced from the sample should not differ significantly from that of the standard. (Fig. 2) Page 2 of 15

3 OUTLINE OF THE METHOD. content is detered (g/kg) by reversed phase high performance liquid chromatography using UV detection at 280 nm and external standard calibration. 3.1 Deteration of by reversed phase HPLC REAGENTS reference standard of known content Acetonitrile (HPLC grade) Phosphoric acid 85 % (puriss. p. a.) Purified water (HPLC grade) Eluent A: 10 mmol phosphoric acid in 1 L purified water Eluent B: acetonitrile APPARATUS High performance liquid chromatograph equipped with an injection system capable to inject 5 µl and an UV spectrophotometric detector operated at 280 nm. Liquid chromatography column, stainless steel, 50 x 4.6 (i.d.) mm, packed with Kinetex C 18; 2.6 µm or equivalent with the same selectivity. Electronic integrator or data system Ultrasonic bath PROCEDURE (a) Operating conditions (typical): Flow rate: 2 ml/ Column temperature: 40 C Injection volume: 5 µl Detector wavelength: 280 nm Mobile phase: Time [] 10 mmol phosphoric acid in 1 L purified water [%v/v] Acetonitrile [%v/v] 0.0 90 10 5.0 85 15 5.1 05 95 6.5 05 95 6.6 90 10 8.5 90 10 Retention time: approximately 4.1 (b) Equilibration of the system. Pump sufficient mobile phase through the column to equilibrate the system. Inject 5 µl portions of the calibration solution C1 and repeat the injections until retention times and peak areas deviate by less than 1 % from the mean for three successive injections. Page 3 of 15

(c) Calibration solution. Weigh in duplicate (to the nearest 0.1 mg) approximately 50 mg (s mg) of the reference standard into separate volumetric flasks (100 ml). Add 50 ml acetonitrile and place the flasks in an ultrasonic bath for 15. Make up the flasks with purified water to just below the calibration mark and allow to cool to ambient temperature. Fill to the mark with purified water and mix thoroughly (Calibration solutions C1, C2) (Fig. 1). (d) Sample preparation. Prepare sample solutions in duplicate for each sample. Weigh (to the nearest 0.1 mg) sufficient sample (w mg) to contain about approximately 50 mg (w mg) of into separate volumetric flasks (100 ml). Add 50 ml acetonitrile and place the flasks in an ultrasonic bath for 15. Make up the flasks with purified water to just below the calibration mark and allow to cool to ambient temperature. Fill to the mark with purified water and mix thoroughly (Sample solutions S1, S2) (Fig. 2). (e) Deteration. Inject in duplicate each sample solution and bracket a series of sample solution injections by injections of the calibration solutions as follows: calibration solution 1, calibration solution 2, calibration solution 1, sample solution 1, sample solution 1, sample solution 2, sample solution 2, calibration solution 1, (C1, C2, C1, S1, S1, S2, S2, C1, ). Detere the peak areas of. (f) Calculation Calculate the response factors from the calibration solutions bracketing the injections of the sample solutions. Average the response factors of the calibration solutions preceding and following the sample solution injections. These must agree within ±1 % of the average otherwise repeat the deteration. Calculate the content of the sample solutions. f i = s x P H S content (g/kg) = H W x f w Where: f i = single response factor f = average response factor H S = peak area of standard in the calibration solution H W = peak area of in the sample solution s = weight of the standard in the calibration solution (mg) w = weight of the sample (mg) P = purity of the standard (g/kg) Repeatability r = 17.75 g/kg at 960 g/kg active ingredient content Reproducibility R = 21.74 g/kg at 960 g/kg active ingredient content Page 4 of 15

FLUPYRADIFURONE ANY OTHER LIQUID 987/AL/M/- 1 Sampling. Take at least 500 ml*. Shake the sample well prior to weighing. *(for this trial less amount is provided) 2 Identity tests. 2.1 HPLC. As for 987/TC/M/- 2.2 UV spectrometry. As for 987/TC/M/- 3. Same approach as for 987/TC/M/- 3.1 Deteration of by reversed phase HPLC As for 987/TC/M/- except Disposable PTFE syringe filter compatible with organic solvents and a 0.45 µm pore diameter or centrifuge. (c) Calibration solution. Weigh in duplicate (to the nearest 0.1 mg) approximately 50 mg (s mg) of the reference standard into separate volumetric flasks (100 ml). Add 50 ml acetonitrile and place the flasks in an ultrasonic bath for 15. Make up the flasks with purified water to just below the calibration mark and allow to cool to ambient temperature. Fill to the mark with purified water and mix thoroughly. Transfer 8 ml of this solution into a separate volumetric flask (100 ml) and make up the flask with acetonitrile / purified water 50 / 50 %v/v to just the calibration mark and allow to cool to ambient temperature. Fill to the mark with acetonitrile / purified water 50 / 50 %v/v and mix thoroughly (Calibration solutions C3, C4) (Fig. 3). (d) Sample preparation. Prepare sample solutions in duplicate for each sample. Weigh (to the nearest 0.1 mg) sufficient sample (w mg) to contain about approximately 2 mg (w mg) of into separate volumetric flasks (50 ml)*. Add 20 ml acetonitrile and place the flasks in an ultrasonic bath for 15. Make up the flasks with acetonitrile to just below the calibration mark and allow to cool to ambient temperature. Fill to the mark with acetonitrile and mix thoroughly. Filter the sample solution through a disposable filter or centrifuge the sample solution (Sample solutions S3, S4) (Fig. 4). * This corresponds to a concentration of 4 mg in 100 ml Repeatability r = 0.00180 g/kg at 0.08 g/kg active ingredient content Reproducibility R = 0.00742 g/kg at 0.08 g/kg active ingredient content Page 5 of 15

FLUPYRADIFURONE EMULSIFIABLE CONCENTRATE 987/EC/M/- 1 Sampling. Take at least 500 ml*. Shake the sample well prior to weighing. *(for this trial less amount is provided) 2 Identity tests. 2.1 HPLC. As for 987/TC/M/- 2.2 UV spectrometry. As for 987/TC/M/- 3. Same approach as for 987/TC/M/- 3.1 Deteration of by reversed phase HPLC As for 987/TC/M/- except Disposable PTFE syringe filter compatible with organic solvents and a 0.45 µm pore diameter or centrifuge. (d) Sample preparation. Prepare sample solutions in duplicate for each sample. Weigh (to the nearest 0.1 mg) sufficient sample (w mg) to contain about approximately 50 mg (w mg) of into separate volumetric flasks (100 ml). Dissolve in 20 ml purified water and add 50 ml acetonitrile and place the flasks in an ultrasonic bath for 15. Make up the flasks with purified water to just below the calibration mark and allow to cool to ambient temperature. Fill to the mark with purified water and mix thoroughly. Filter the sample solution through a disposable filter or centrifuge the sample solution (Sample solutions S5, S6) (Fig. 5). Repeatability r = 0.94 g/kg at 64.7 g/kg active ingredient content Reproducibility R = 1.32 g/kg at 64.7 g/kg active ingredient content Page 6 of 15

FLUPYRADIFURONE EMULSION, OIL IN WATER 987/EW/M/- 1 Sampling. Take at least 500 ml*. Shake the sample well prior to weighing. *(for this trial less amount is provided) 2 Identity tests. 2.1 HPLC. As for 987/TC/M/- 2.2 UV spectrometry. As for 987/TC/M/- 3. Same approach as for 987/TC/M/- 3.1 Deteration of by reversed phase HPLC Same approach as for 987/EC/M/- (Sample solutions S7, S8) (Fig. 6) Repeatability r = 0.94 g/kg at 25 g/kg active ingredient content Reproducibility R = 2.34 g/kg at 25 g/kg active ingredient content FLUPYRADIFURONE FLOWABLE CONCENTRATE FOR SEED TREATMENT 987/FS/M/- 1 Sampling. Take at least 500 ml*. Shake the sample well prior to weighing. *(for this trial less amount is provided) 2 Identity tests. 2.1 HPLC. As for 987/TC/M/- 2.2 UV spectrometry. As for 987/TC/M/- 3. Same approach as for 987/TC/M/- 3.1 Deteration of by reversed phase HPLC Same approach as for 987/EC/M/- (Sample solutions S9, S10) (Fig. 7) Repeatability r = 8.70 g/kg at 407 g/kg active ingredient content Reproducibility R = 11.71 g/kg at 407 g/kg active ingredient content Page 7 of 15

4 Suspensibility REAGENTS AND APPARATUS as for MT 184 PROCEDURE (a) Preparation of suspension and deteration of sedimentation. MT 184. (b) Deteration of in the bottom 25 ml of suspension: After removal of the top 225 ml of suspension transfer approx. 250 mg* out of the remaining and well homogenized 25 ml to a 100 ml volumetric flask and add 20 ml purified water and 50 ml acetonitrile. To dissolve the substance, place the flask in an ultrasonic bath for 15 and make up the flask with purified water to just below the calibration mark. Wait until the temperature has stabilized, then fill the flask up to the calibration mark with purified water. Detere the mass of flupyradifurone (Q g) by 987/TC/M/-). * This is calculated for a 50% suspension, in case of other concentrations the volume has to be adjusted but it has to be ensured to work within the linear range. FLUPYRADIFURONE SUSPENSION CONCENTRATE 987/SL/M/- 1 Sampling. Take at least 500 ml*. Shake the sample well prior to weighing. *(for this trial less amount is provided) 2 Identity tests. 2.1 HPLC. As for 987/TC/M/- 2.2 UV spectrometry. As for 987/TC/M/- 3. Same approach as for 987/TC/M/- 3.1 Deteration of by reversed phase HPLC Same approach as for 987/EC/M/- (Sample solutions S11, S12) (Fig. 8) Repeatability r = 3.20 g/kg at 171 g/kg active ingredient content Reproducibility R = 3.29 g/kg at 171 g/kg active ingredient content Page 8 of 15

FLUPYRADIFURONE WATER DISPERSABLE GRANULE 987/WG/M/- 1 Sampling. Take at least 500 g*. Grind the sample thoroughly in a mortar. *(for this trial less amount is provided; please grind the entire sample) 2 Identity tests. 2.1 HPLC. As for 987/TC/M/- 2.2 UV spectrometry. As for 987/TC/M/- 3. Same approach as for 987/TC/M/- 3.1 Deteration of by reversed phase HPLC Same approach as for 987/EC/M/- (Sample solutions S13, S14) (Fig. 9) Repeatability r = 2.91 g/kg at 120 g/kg active ingredient content Reproducibility R = 3.56 g/kg at 120 g/kg active ingredient content 4 Suspensibility. As for 987/FS/M/- except (b) Deteration of in the bottom 25 ml of suspension. After removal of the top 225 ml of suspension transfer approx. 2700 mg* out of the remaining and well homogenized 25 ml to a 100 ml volumetric flask and add 20 ml purified water and 50 ml acetonitrile. To dissolve the substance, place the flask in an ultrasonic bath for 15 and make up the flask with purified water to just below the calibration mark. Wait until the temperature has stabilized, then fill the flask up to the calibration mark with purified water. Detere the mass of flupyradifurone (Q g) by 987/AL/M/-) * This is calculated for a 1.2% suspension, in case of other concentrations the volume has to be adjusted but it has to be ensured to work within the linear range. Page 9 of 15

55.0 50.0 KM0756_170420b_VB1-AM029216MF1_Pecision #4 Lin 3 Wdh. BYI 02960 % 40.0 30.0 20.0 10.0 0.0 nm -5.0 190 200 225 250 275 300 325 350 375 400 Fig. 1 UV-Spectrum of Fig. 2 Infrared Spectrum of Page 10 of 15

500 400 300 200 100-20 Fig. 3 Chromatogram of (Standard) 500 400 300 200 100-20 Fig. 4 Chromatogram of TC Page 11 of 15

50.0 40.0 30.0 20.0 10.0 0.0-10.0 Fig. 5 Chromatogram of (Standard for AL formulation) 50.0 40.0 30.0 20.0 10.0 0.0-10.0 Fig. 6 Chromatogram of AL Page 12 of 15

500 400 300 200 100-20 Fig. 7 Chromatogram of EC 500 400 300 200 100-20 Fig. 8 Chromatogram of EW Page 13 of 15

500 400 300 200 100-20 Fig. 9 Chromatogram of FS 500 400 300 200 100-20 Fig. 10 Chromatogram of SL Page 14 of 15

500 400 300 200 100-20 Fig. 11 Chromatogram of WG Page 15 of 15